ACR Open Rheumatology Vol. 4, No. 8, August 2022, pp 644

© 2022 The Authors. *ACR Open Rheumatology* published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

LETTER TO THE EDITOR

DOI 10.1002/acr2.11438

Antineutrophil cytoplasmic antibody, glomerulonephritis and inactivated SARS-CoV-2 vaccine: comment on the article by Garcia et al

To the Editor:

We would like to share our ideas on the article "Clinical Images: Severe proteinase 3 antineutrophil cytoplasmic antibody glomerulonephritis temporally associated with Sinovac Biotech's inactivated SARS-CoV-2 vaccine" (1). Garcia et al concluded that theirs was "the first report of AAV [adeno-associated virus] possibly triggered by an inactivated COVID-19 [coronavirus disease 2019] vaccine" (1). We agree that COVID-19 might induce adverse effects and AAV might be a possible problem. An important concern is regarding a possible confounding disorder that might induce AAV. For a COVID-19 vaccine recipient, it is possible that there might be a forgotten comorbidity. For example, dengue might exist in a COVID-19 vaccine recipient (2), and it is also a possible cause of AAV (3).

Author disclosures are available at https://onlinelibrary.wiley.com/ action/downloadSupplement?doi=10.1002%2Facr2.11438&file=acr211438sup-0001-Disclosureform.pdf.

> Rujittika Mungmunpuntipantip, PhD *Private Academic Consultant Bangkok, Thailand* Viroj Wiwanitkit, MD *Dr DY Patil University Pune, India*

American College

of RHEUMATOLOGY

Empowering Rheumatology Professionals

- Garcia DS, Martins C, da Fonseca EO, de Carvalho VCP, de Rezende RPV. Clinical Images: severe proteinase 3 antineutrophil cytoplasmic antibody glomerulonephritis temporally associated with Sinovac Biotech's inactivated SARS-CoV-2 vaccine. ACR Open Rheumatol 2022;4:277–8.
- Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost 2021;27: 1076029621104.
- Kakoullis L, Parperis K, Papachristodoulou E, Panos G. Infectioninduced myeloperoxidase specific antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis: a systematic review. Clin Immunol 2020;220:108595.